M&A Analysis: February, Onco And Cardio Deals Invade Frosty Month
Medtech Insight recorded nine newly announced deals in February, a decline from the 17 deals recorded in January 2017 and the 12 noted in the same period last year. Nevertheless, it proved to be a busy month in the oncology and cardiovascular space, with radiotherapy specialist Varian racking up two deals in the same month to expand its cancer portfolio.
You may also be interested in...
More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.
As it continues to build-up its medical device business, Japanese group Teijin has acquired MedTech Heart, which is developing a maglev ventricular assist device for heart failure patients.
Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.